TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
MA.39
NCT03488693
 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Breast |
Dr. Pierre Rousseau
Diane Trudel
514-890-8000 poste 11181
|
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
MA.39
NCT03488693
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Breast |
Dr. Sawyna Provencher
Sophie Couture
819-346-1110 poste 14311
|
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
MA.39
NCT03488693
Recruiting
|
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Breast |
Dr. Thierry Muanza
Arielle Langburt
514-340-8222 poste 26801
|
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
MA.39
NCT03488693
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Breast |
Dr. Valérie Théberge
Josée Allard
418-525-4444 poste 16730
|
A randomized trial of regional radiotherapy in biomarker low risk node positive breast cancer
MA.39
NCT03488693
Recruiting
|
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
|
Breast |
Dr. Isabelle Roy
Solange Tremblay
450-668-1010 poste 23603
|
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
MA.39 (TAILOR RT)
NCT03488693
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Breast |
Dr. Timothy David Lymberiou
Caroline Hivon
450-466-5000 poste 2164
|
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
TROPION-Breast05
NCT06103864
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Breast |
Dr. Samuel Martel
Christine Giard
450-466-5000 poste 2278
|
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
CAMBRIA-1
NCT05774951
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Breast |
Dr. Samuel Martel
Christine Giard
450-466-5000 poste 2278
|
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
TROPION-Breast05
NCT06103864
Recruiting
|
SITE GLEN
|
Breast |
Dr. Jamil Asselah
Ryan Liu
514-934-1934 poste 34905
|
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
ELISA
NCT04797299
Recruiting
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
Breast |
Dr. François Vincent
Marie-Ève Caron
819-697-3333 poste 63238
|
Groupe d'étude en oncologie du Québec